Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.

Rodriguez-Aller M, Kaufmann B, Guillarme D, Stella C, Furrer P, Rudaz S, El Zaoui I, Valamanesh F, Di Tommaso C, Behar-Cohen F, Veuthey JL, Gurny R.

Eur J Pharm Biopharm. 2012 Apr;80(3):544-52. doi: 10.1016/j.ejpb.2011.11.017. Epub 2011 Dec 3.

PMID:
22155591
2.

A novel water-soluble cyclosporine A prodrug: ocular tolerance and in vivo kinetics.

Lallemand F, Furrer P, Felt-Baeyens O, Gex-Fabry M, Dumont JM, Besseghir K, Gurny R.

Int J Pharm. 2005 May 13;295(1-2):7-14.

PMID:
15847987
3.

Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.

Di Tommaso C, Bourges JL, Valamanesh F, Trubitsyn G, Torriglia A, Jeanny JC, Behar-Cohen F, Gurny R, Möller M.

Eur J Pharm Biopharm. 2012 Jun;81(2):257-64. doi: 10.1016/j.ejpb.2012.02.014. Epub 2012 Mar 16.

PMID:
22445900
4.

In vivo distribution and ex vivo permeation of cyclosporine A prodrug aqueous formulations for ocular application.

Rodriguez-Aller M, Guillarme D, El Sanharawi M, Behar-Cohen F, Veuthey JL, Gurny R.

J Control Release. 2013 Aug 28;170(1):153-9. doi: 10.1016/j.jconrel.2013.04.019. Epub 2013 May 3.

PMID:
23648835
5.

Biological conversion of a water-soluble prodrug of cyclosporine A.

Lallemand F, Varesio E, Felt-Baeyens O, Bossy L, Hopfgartner G, Gurny R.

Eur J Pharm Biopharm. 2007 Sep;67(2):555-61. Epub 2007 Mar 19.

PMID:
17475453
6.

A water-soluble prodrug of cyclosporine A for ocular application: a stability study.

Lallemand F, Perottet P, Felt-Baeyens O, Kloeti W, Philippoz F, Marfurt J, Besseghir K, Gurny R.

Eur J Pharm Sci. 2005 Sep;26(1):124-9.

PMID:
15978789
7.

Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.

Aksungur P, Demirbilek M, Denkbaş EB, Vandervoort J, Ludwig A, Unlü N.

J Control Release. 2011 May 10;151(3):286-94. doi: 10.1016/j.jconrel.2011.01.010. Epub 2011 Jan 15.

PMID:
21241752
8.

Conversion of cyclosporine A prodrugs in human tears vs rabbits tears.

Lallemand F, Felt-Baeyens O, Rudaz S, Hamel AR, Hubler F, Wenger R, Mutter M, Besseghir K, Gurny R.

Eur J Pharm Biopharm. 2005 Jan;59(1):51-6.

PMID:
15567301
9.

Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.

Sall K, Stevenson OD, Mundorf TK, Reis BL.

Ophthalmology. 2000 Apr;107(4):631-9. Erratum in: Ophthalmology 2000 Jul;107(7):1220.

PMID:
10768324
10.

A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation.

Di Tommaso C, Valamanesh F, Miller F, Furrer P, Rodriguez-Aller M, Behar-Cohen F, Gurny R, Möller M.

Invest Ophthalmol Vis Sci. 2012 Apr 30;53(4):2292-9. doi: 10.1167/iovs.11-8829.

PMID:
22427552
11.
12.

Cyclosporine Amicellar delivery system for dry eyes.

Kang H, Cha KH, Cho W, Park J, Park HJ, Sun BK, Hyun SM, Hwang SJ.

Int J Nanomedicine. 2016 Jun 21;11:2921-33. doi: 10.2147/IJN.S107569. eCollection 2016.

13.

Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.

Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME.

Cornea. 2008 Jan;27(1):64-9. doi: 10.1097/ICO.0b013e318158f6dc.

PMID:
18245969
14.

Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits.

Daull P, Lallemand F, Philips B, Lambert G, Buggage R, Garrigue JS.

Cornea. 2013 Mar;32(3):345-54. doi: 10.1097/ICO.0b013e31825e83f4.

PMID:
23023401
16.

Cyclosporine A delivery to the eye: a pharmaceutical challenge.

Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R.

Eur J Pharm Biopharm. 2003 Nov;56(3):307-18. Review.

PMID:
14602172
17.

Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.

Daull P, Feraille L, Barabino S, Cimbolini N, Antonelli S, Mauro V, Garrigue JS.

Exp Eye Res. 2016 Dec;153:159-164. doi: 10.1016/j.exer.2016.10.016. Epub 2016 Oct 21.

18.

Clinical review: topical ophthalmic use of cyclosporin A.

Utine CA, Stern M, Akpek EK.

Ocul Immunol Inflamm. 2010 Oct;18(5):352-61. doi: 10.3109/09273948.2010.498657. Review.

PMID:
20735287
19.

Ocular delivery systems for poorly soluble drugs: an in-vivo evaluation.

Luschmann C, Herrmann W, Strauss O, Luschmann K, Goepferich A.

Int J Pharm. 2013 Oct 15;455(1-2):331-7. doi: 10.1016/j.ijpharm.2013.07.002. Epub 2013 Jul 16.

PMID:
23867983
20.

Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsion.

Karn PR, Kim HD, Kang H, Sun BK, Jin SE, Hwang SJ.

Int J Nanomedicine. 2014 Aug 8;9:3791-800. doi: 10.2147/IJN.S65601. eCollection 2014.

Supplemental Content

Support Center